Skip to main content

Congress Materials

Filter
Filter events:
Clear filters

44 result(s)

Filter
Select topic(s):
Content type:
Clear filters

*Includes seizure clusters and acute or prolonged seizures

304 result(s)

“How quickly will I feel better with this new drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
Deodhar Atul, Nikiphorou Elena, Abhijeet Danve et al.
A Novel International Patient Registry in Myasthenia Gravis Linking Clinical and Patient-Reported Outcomes Data: The Vitaccess Real MG (VRMG) Registry
Fatemeh Amini, Jack Lawrence, Sally Vincent et al.
A Post-Hoc Evaluation of Fenfluramine With or Without Vagus Nerve Stimulation in Lennox-Gastaut Syndrome Clinical Trials
Lieven Lagae, Kelly G. Knupp, Joseph Sullivan et al.
A retrospective claims study evaluating mortality in patients with Lennox-Gastaut or Dravet syndrome in the United States
Rejena Ameen, PharmD, Elaine C. Wirrell et al.
A Stratified Analysis of Efficacy and Safety of Fenfluramine in Patients With Dravet Syndrome
Rima Nabbout, Joseph Sullivan, Stéphane Auvin et al.
A stratified analysis of efficacy and safety of fenfluramine in patients with Dravet syndrome
Rima Nabbout, Joseph Sullivan, Stéphane Auvin et al.
Access Barriers to Antiseizure Medications and Neurologists: Effects on Epilepsy Stakeholder Experiences
Herbert Peeples, Emily Achter, Christopher Dieyi et al.
Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Gensler S. Lianne, Marzo-Ortega Helena, Taieb Vanessa et al.
Analysis of Safety, Tolerability and Clinical Global Impression-Improvement Scale Ratings in Patients With Dravet Syndrome Enrolled as Adults in a Fenfluramine Open-Label Extension Study
Ingrid E Scheffer, Orrin Devinsky, Milka Pringsheim et al.
Antiseizure Medication Regimen Adjustment After Fenfluramine Initiation: Lessons Learned From European Early Access Program in Pediatric and Adult Patients With Dravet Syndrome
Renzo Guerrini, Milka Pringsheim, Ángel Aledo-Serrano et al.
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
McBride Sandra, Węgłowska Jolanta, Wolf Peter et al.
Association of Hidradenitis Suppurativa Flares and the Menstrual Cycle: A Prospective Cohort Study
Harbour Victoria, Andres-Terre Helena, Maria A. Aleshin et al.
Association of Hidradenitis Suppurativa Flares and the Menstrual Cycle: A Prospective Cohort Study
Harbour Victoria, Andres-Terre Helena, Aleshin Maria et al.
Automated assessment of sleep in healthy pediatrics from simulated behind-the-ear EEG
Benjamin Wittevrongel, Tanja Hellier, Julie Nys et al.
Automated Assessment of Sleep in Patients With Dravet Syndrome From Simulated Behind-the-Ear EEG
Benjamin Wittevrongel, Tanja Hellier, Jan Vandenneucker et al.
Barriers and Facilitators to Quality HS Biologic Care and Outcomes for the Medicaid Population Across US States
Daveluy Steven, Brooks Brindley, Hazelett Brent et al.
Bimekizumab 2-year Efficacy by Prior Biologic Use in Moderate to Severe HS: Data from BE HEARD EXT
Vivian Y. Shi, Hsiao Jennifer, Christopher J Sayed et al.
Bimekizumab 2-Year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT
Christopher J Sayed, Martina L. Porter, Hamzavi Iltefat et al.
Bimekizumab 2-year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT
Christopher J Sayed, Martina L. Porter, Hamzavi Iltefat et al.
Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT
Lauren A.V. Orenstein, Vivian Y. Shi, Lev-Tov Hadar et al.
Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT
Lauren A.V. Orenstein, Vivian Y. Shi, Lev-Tov Hadar et al.
Bimekizumab 2-year Maintenance of Response in Moderate to Severe HS: Data from BE HEARD EXT
Martina L. Porter, Chovatiya Raj, Gulliver Wayne et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from BE BRIGHT and BE RADIANT
Langley G. Richard, Joseph F. Merola, Thaci Diamant et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
M. Lebwohl, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Merola F. Joseph, Gottlieb B. Alice, Soung Jennifer et al.
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Joseph F. Merola, Alice B Gottlieb, Soung Jennifer et al.
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Merola F. Joseph, Gottlieb B. Alice, Soung Jennifer et al.
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Joseph F. Merola, Alice B Gottlieb, Soung Jennifer et al.
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Joseph F. Merola, Alice B Gottlieb, Soung Jennifer et al.
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Blauvelt Andrew, Foley Peter, Langley G. Richard et al.
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Blauvelt Andrew, Foley Peter, Langley G. Richard et al.
Bimekizumab achievement of ‘super response’ using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Lebwohl Mark, Langley G. Richard, Strober Bruce et al.
Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year
Garg Amit, Davis Leah, Taieb Vanessa et al.
Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Armstrong April, Elewski Boni, Rich Pheobe et al.
Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Armstrong April, Elewski Boni, Rich Pheobe et al.
Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
Alexa B. Kimball, Amit Garg, Lev-Tov Hadar et al.
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Blauvelt Andrew, Merola F. Joseph, Kokolakis Georgios et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Blauvelt Andrew, Conrad Curdin, Costanzo Antonio et al.
Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials
Garg Amit, Armstrong April, Sofen Howard et al.
Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials
Amit Garg, Armstrong April, Sofen Howard et al.
Bimekizumab effect on pain severity and impact in moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
Lauren A.V. Orenstein, Vivian Y. Shi, Gottlieb B. Alice et al.
Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II
Bechara G. Falk, Forman Seth, Garg Amit et al.
Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II
Bechara G. Falk, Forman Seth, Garg Amit et al.
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Strober Bruce, Krueger G. James, Magnolo Nina et al.
Bimekizumab Efficacy Across Subgroups of Patients With Moderate to Severe Plaque Psoriasis: Pooled Analysis From up to 3 Years of Treatment in 5 Phase 3/3b Clinical Trials
Strober Bruce, Krueger G. James, Magnolo Nina et al.
Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study
Okubo Yukari, Tada Yayoi, Takahashi Hidetoshi et al.
Bimekizumab efficacy and safety in patients with psoriatic arthritis and psoriasis: Up to 2-year results from two phase 3 studies
Thaci Diamant, Alice B Gottlieb, Akihiko Asahina et al.
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Thaci Diamant, Akihiko Asahina, Wolf-Henning Boehncke et al.
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Thaci Diamant, Akihiko Asahina, Wolf-Henning Boehncke et al.
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Lebwohl Mark, Papp Kim, Ehst Benjamin et al.
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Lebwohl Mark, Papp Kim, Ehst Benjamin et al.
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Lebwohl Mark, Papp Kim, Ehst Benjamin et al.
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Lebwohl Mark, Papp Kim, Ehst Benjamin et al.
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Christos C Zouboulis, Garg Amit, Christopher J Sayed et al.
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Christos C Zouboulis, Garg Amit, Christopher J Sayed et al.
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Christos C Zouboulis, Amit Garg, Sayed J. Christopher et al.
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Zouboulis C. Christos, Garg Amit, Sayed J. Christopher et al.
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Zouboulis C. Christos, Amit Garg, Christopher J Sayed et al.
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-term Results from a Phase 3 Study and Open-Label Extension
Thaci Diamant, Puig Luis, Joseph F. Merola et al.
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Thaci Diamant, Puig Luis, Merola F. Joseph et al.
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Blauvelt Andrew, Khattri Saakshi, Rich Phoebe et al.
Bimekizumab efficacy by body region in plaque psoriasis: Comparative analyses from four phase 3/3b studies
Savage J. Laura, Pinter Andreas, Crowley Jeffrey et al.
Bimekizumab efficacy by disease duration in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Chovatiya Raj, Forman Seth, Alavi Afsaneh et al.
Bimekizumab efficacy by patient subgroups in moderate to severe hidradenitis suppurativa: 2-year phase 3 results from BE HEARD EXT
Christopher J Sayed, Martina L. Porter, Kokolakis Georgios et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Strober Bruce, Lebwohl Mark, Foley Peter et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Strober Bruce, Lebwohl Mark, Foley Peter et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Strober Bruce, Lebwohl Mark, Foley Peter et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Strober Bruce, Lebwohl Mark, Foley Peter et al.
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in fatigue observed in two phase 3 studies
Alice B Gottlieb, Augustin Matthias, Lambert Jo et al.
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
Gottlieb B. Alice, Warren B. Richard, Augustin Matthias et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
Armstrong April, Feldman Steven, Gisondi Paolo et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Gottlieb B. Alice, Asahina Akihiko, Tsai F. Tsen et al.
Bimekizumab efficacy in patients with plaque psoriasis: A post hoc stratification by weight over 4 years in BE BRIGHT
Maria-Angeliki Gkini, Lopez-Ferrer Anna, Magnolo Nina et al.
Bimekizumab efficacy in patients with psoriasis and concurrent hypertension, elevated body mass index, or hyperglycemia: Long-term results from BE BRIGHT
Armstrong April, Feldman R. Steven, Gisondi Paolo et al.
Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials
Han George, Gottlieb B. Alice, Armstrong April et al.
Bimekizumab impact on clinical markers of liver fibrosis and key liver parameters in patients with moderate to severe plaque psoriasis: Long-term pooled data from BE BRIGHT
Gisondi Paolo, Lebwohl Mark, Strober Bruce et al.
Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II
Bechara G. Falk, Sayed J. Christopher, Goldberg Stephanie et al.
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Merola F. Joseph, Mease J. Philip, Deodhar Atul et al.
Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT
Tzellos Thrasyvoulos, Christopher J Sayed, Alice B Gottlieb et al.
Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II
Zouboulis C Christos, Hsiao Jennifer, Reguiai Ziad et al.
Bimekizumab Impact on Draining Tunnels Over 2 Years in HS: Data from BE HEARD EXT
Christos C Zouboulis, Hsiao Jennifer, Garg Amit et al.
Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II
Tzellos Thrasyvoulos, Hsiao Jennifer, Martina L. Porter et al.
Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II
Tzellos Thrasyvoulos, Hsiao Jennifer, Martina L. Porter et al.
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Naik B Haley, Daveluy Steven, Errol Prens et al.
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Ingram R. John, Daveluy Steven, Errol Prens et al.
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
John R Ingram, Daveluy Steven, Errol Prens et al.
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
John R Ingram, Daveluy Steven, Errol Prens et al.
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Joseph F. Merola, Philip J Mease, Deodhar Atul et al.
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Morita Akimichi, Merola F. Joseph, Coates C. Laura et al.
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Szepietowski C. Jacek, Lev-Tov Hadar, Shi Y Vivian et al.
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Szepietowski C. Jacek, Lev-Tov Hadar, Shi Y Vivian et al.
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Szepietowski C. Jacek, Lev-Tov Hadar, Shi Y Vivian et al.
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Umezawa Yoshinori, Merola F. Joseph, Coates C. Laura et al.
Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
Augustin Matthias, Cather Jennifer, Papp A. Kim et al.
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Merola F. Joseph, Xenofon Baraliakos, Thaci Diamant et al.
Bimekizumab in routine clinical practice: Baseline characteristics and treatment history of patients with moderate to severe plaque psoriasis from the second interim analysis of ELEVATE
Ralph von Kiedrowski, Thaci Diamant, Stavermann Thomas et al.
Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Kokolakis Georgios, Han George, Pariser David et al.
Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Kokolakis Georgios, Han George, Pariser David et al.
Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Mean percentage improvement in clinical outcomes over 4 years
Gerdes Sascha, Costanzo Antonio, Fernandez-Peñas Pablo et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies
Tillett William, Tanaka Yoshiya, Thaci Diamant et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-αα Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
Tillett R. Willian, Merola F. Joseph, Tanaka Yoshiya et al.
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Proft Fabian, Desiree van der Heijde, Sergio Schwartzman et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Proft Fabian, Desiree van der Heijde, Xenofon Baraliakos et al.
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Lebwohl Mark, Richard B Warren, Foley Peter et al.
Bimekizumab maintenance of response from the end of pivotal trials through 4 years: Results in patients with moderate to severe plaque psoriasis from BE BRIGHT
Gordon B. Kenneth, Cather Jennifer, Pariser David et al.
Bimekizumab PASI response levels in Week 16 PASI responders with moderate to severe plaque psoriasis through 4 years: Results from BE BRIGHT
Thaci Diamant, Rosmarin David, Crowley Jeffrey et al.
Bimekizumab reduced psoriatic arthritis impact in patients with psoriasis: Up to 2-year results from two phase 3 studies
Gossec Laure, Gladman D. Dafna, Gisondi Paolo et al.
Bimekizumab reduces systemic inflammation and cardiovascular risk gene signatures in psoriatic disease
Cutcutache Ioana, Victoria Svinti MacLeod, Valeo Flavia et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Langley G. Richard, Fernandez-Peñas Pablo, Krueger James et al.
Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicenter, randomized, open-label studies
Bagel Jerry, Knapp Bertram, Vaux Thomas et al.
Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicentre, randomised, open-label studies
Bagel Jerry, Knapp Bertram, Vaux Thomas et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety and tolerability in patients with moderate to severe hidradenitis suppurativa: 2-year results from BE HEARD EXT
John R Ingram, Naik B Haley, Christos C Zouboulis et al.
Bimekizumab Safety in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Rates of Hepatic Events and Transaminase Elevations in Phase 3 Trials
Mease J. Philip, Dubreuil Maureen, Merola F. Joseph et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Warren B. Richard, Okubo Yukari, Spelman Lynda et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Thaci Diamant, Imafuku Shinichi, Gooderham Melinda et al.
Bimekizumab simultaneous skin and nail clearance in patients with psoriasis: Assessing comparative efficacy in four phase 3/3b studies
Merola F. Joseph, Warren B. Richard, Thaci Diamant et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Blauvelt Andrew, Duffin C. Kristina, Magnolo Nina et al.
Bimekizumab treatment history and clinical outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE
Thaci Diamant, Asadullah Khusru, Ralph von Kiedrowski et al.
Bimekizumab treatment history and quality of life outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE
Asadullah Khusru, Augustin Matthias, Korge Bernhard et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni, Mease J. Philip, Merola F. Joseph et al.
Bimekizumab treatment in plaque psoriasis resulted in a rapid and deep normalisation of molecular signatures associated with PASI sub-components, that preceded clinical skin clearance
Cutcutache Ioana, Valeo Flavia, Rastrick Joe et al.
Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response
Cutcutache Ioana, Skelton Andrew, Kolivras Athanassios et al.
Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response
Cutcutache Ioana, Skelton Andrew, Kolivras Athanassios et al.
Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two phase 3 studies
Maksymowych P. Walter, Ramiro Sofia, Poddubnyy Denis et al.
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Maksymowych P. Walter, Ramiro Sofia, Poddubnyy Denis et al.
Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Merola F. Joseph, Gottlieb B. Alice, Ink Barbara et al.
Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
Merola F. Joseph, Thaci Diamant, Ink Barbara et al.
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
Gottlieb B. Alice, Merola F. Joseph, Ink Barbara et al.
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 2-year results from two phase 3 studies
Alice B Gottlieb, Akihiko Asahina, Thaci Diamant et al.
Bimekizumab Treatment was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Ramiro Sofia, Proft Fabian, Sengupta Raj et al.
Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
J. F. Merola, C. Conrad, P. Foley et al.
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Mease J. Philip, Tillett William, Maarten de Wit et al.
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Mease J. Philip, Tillett R. Willian, Maarten de Wit et al.
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Philip J Mease, Tillett William, Maarten de Wit et al.
Bimekizumab: Exploring the fast onset, high level, and durability of clinical and molecular responses in patients with psoriatic disease – Design and rationale behind the exploratory, multicentre, open-label phase 3b BE UNIQUE study
Johann E. Gudjonsson, Joseph F. Merola, Warren B. Richard et al.
Bimekizumab: Network meta-analysis to establish comparative efficacy in moderate-to-severe hidradenitis suppurativa patients
Haley Naik, Davis Leah, Mørup Michael Frank et al.
Brivaracetam adjunctive therapy in earlier treatment lines in adults with focal-onset seizures in Europe and Canada: second interim results of 12-month real-world data from BRITOBA
Susanne Knake, Marco de Curtis, Eliane Kobayashi et al.
Brivaracetam monotherapy patient characteristics, treatment patterns, and healthcare resource utilization among patients with epilepsy: a cohort study using US claims data
Beade Numbere, Hervé Besson, Anna Kuba et al.
Caregiver Versus Investigator Clinical Global Impression-Improvement Ratings in Fenfluramine Clinical Trials
Lieven Lagae, Kelly Knupp, J Helen Cross et al.
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef S. Smolen, Gerd Burmester, Yoshiya Tanaka et al.
Characteristics, Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States
Zhou Jiachen, Nilius Sigrid, Pilipczuk Olga et al.
Characterization, Healthcare Resource Utilization, and Costs of Health Equity Clusters of Medicaid-Insured Patients With Epilepsy: An Exploratory Machine Learning Approach
Herbert Peeples, Keshia Maughn, Christopher Dieyi et al.
Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-Hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study
Habib A. Ali, Kaminski J. Henry, Grosskreutz Julian et al.
Comparative Effectiveness of Fenfluramine Versus Cannabidiol in Dravet Syndrome: A Numbers Needed to Treat Indirect Comparison Analysis
Carlos H. Arteaga Duarte, Sandeep Kiri, Vanessa Taieb et al.
Compliance to daily self-administered subcutaneous zilucoplan in patients with generalized myasthenia gravis: A post hoc analysis of the RAISE-XT study
Ruzhansky Katherine, Freimer Miriam, M. Isabel Leite et al.
Comprehensive Analysis of Lennox-Gastaut Syndrome in Europe: Treatment Patterns, Healthcare Utilisation, and Quality of Life
Adam Strzelczyk, Antonio Gil-Nagel, Pasquale Striano et al.
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Weiss D. Michael, Hewamadduma Channa, M. Isabel Leite et al.
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Weiss D. Michael, Hewamadduma Channa, M. Isabel Leite et al.
Correlation between MG Symptoms PRO and existing MG‑specific outcome scores in the Phase 3 MycarinG study: Post hoc analysis
Pascuzzi M. Robert, Antozzi Carlo, Habib A. Ali et al.
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Freimer Miriam, Genge Angela, Hewamadduma Channa et al.
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Freimer Miriam, Genge Angela, Hewamadduma Channa et al.
Corticosteroid dose tapering in patients with generalized myasthenia gravis on zilucoplan: Interim analysis of RAISE-XT
Hewamadduma Channa, Genge Angela, Freimer Miriam et al.
Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
M. Isabel Leite, Freimer Miriam, Genge Angela et al.
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan E. B. Clowse, David A. Isenberg, Joan T. Merrill et al.
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Alex S. Powlesland, Cutcutache Ioana, Skelton Andrew et al.
Developing needs-driven medical education for healthcare professionals in myasthenia gravis
James F. Howard Jr., Mantegazza Renato, Narayanaswami Pushpa et al.
Development and validation of a claims-based algorithm for hidradenitis suppurativa severity
Maria C Schneeweiss, P Anand, A Mostaghimi et al.
Development of an Electronic Decision-Assisting Tool for the Evaluation of the Likelihood of Lennox-Gastaut Syndrome (LGS) Diagnosis
Nicola Specchio, Alexis Arzimanoglou, Stéphane Auvin et al.
Disruptive Impacts of Developmental and Epileptic Encephalopathies on Patient and Family Life: A Quality-of-Life Survey
Laurie D. Bailey, Tracy Dixon-Salazar, Mary Anne Meskis et al.
Disruptive impacts of developmental and epileptic encephalopathies on patient and family life: a quality-of-life survey
Mercedes Martin, Laurie D. Bailey, Tracy Dixon-Salazar et al.
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Josef S. Smolen, Ted R. Mikuls, James Galloway et al.
Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-Label Extension Studies
Mahuwala K. Zabeen, Grosskreutz Julian, Habib A. Ali et al.
Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry
Ogdie R. Alexis, Song Chao, Middaugh Nicole et al.
Effect of rozanolixizumab on bulbar and respiratory symptoms in patients with generalized myasthenia gravis: Post hoc item-level analysis of MycarinG
Wallace Thomas, Antozzi Carlo, Grosskreutz Julian et al.
Effect of rozanolixizumab on myasthenia gravis-specific outcome subdomain scores: Post hoc analyses from the Phase 3 MycarinG study
Pascuzzi M. Robert, Habib A. Ali, Vissing John et al.
Effect of rozanolixizumab on ocular symptoms in patients with generalized myasthenia gravis: A post hoc item-level analysis of myasthenia gravis-specific outcomes in MycarinG
Mahuwala K. Zabeen, Ali Habib, Pascuzzi M. Robert et al.
Effect of zilucoplan on myasthenia gravis-specific outcome subdomain scores in RAISE: A Phase 3 study
Weiss D. Michael, Constantine Farmakidis, Freimer Miriam et al.
Effectiveness and Tolerability of Adjunctive Brivaracetam in Adults With Focal-Onset Seizures on One Specific Antiseizure Medication: Post Hoc Analysis of Interim Real‐World Data From BRITOBA
Edouard Hirsch, Adrien Didelot, Dimitrios Bourikas et al.
Effectiveness and Tolerability of Brivaracetam in Adults With Epilepsy Etiology of Cerebral Neoplasm, Cerebrovascular Accident, or Cranial Trauma: Pooled Data Analyses From Two Real-World Studies
Hina Dave, Michael R Sperling, Brian Moseley et al.
Efficacy of zilucoplan in patients with generalized myasthenia gravis without prior immunoglobulin or plasma exchange in the RAISE study
James F. Howard Jr., Masuda Masayuki, Boroojerdi Babak et al.
Evaluating mental health in caregivers of patients with Dravet syndrome: a systematic review
Bobby Jacob, Michael Scott Perry, Christoph Helmstaedter et al.
Evidence of misdiagnosis in administrative claims data for individuals with myasthenia gravis
Thompson Judith, Zhang Bo, Liberman N. Joshua et al.
Experiences of women of childbearing age with epilepsy throughout their motherhood journey: results from a social media listening study
Michelle Manzo, Gus A Baker, Michelle Shell et al.
Expert Consensus Recommendations on Seizure Emergencies Suitable for Rapid and Early Seizure Termination (REST) and Timing of Intervention
Jesus Eric Pina-Garza, Michael Chez, James Cloyd et al.
Fenfluramine Efficacy Trajectories in Placebo or Treatment Groups From Randomized Controlled Trial to Open-Label Extension
Rima Nabbout, Orrin Devinsky, Lieven Lagae et al.
Fenfluramine Increases Seizure-Free Days in Patients With Lennox-Gastaut Syndrome
Stéphane Auvin, Ingrid E. Scheffer, Antonio Gil-Nagel et al.
Fenfluramine Safety: An Update From Post-Marketing Reports
Rebecca Zhang-Roper, Najla Dickson, Madhur Goyal et al.
Fragment Crystallizable (Fc)-Free Certolizumab Pegol is not Bound by Rheumatoid Factors, while Fc Containing Biological DMARDs Are, Driving Immune Complex Formation and Cellular Clearance
Susanna R. Bidgood, Sophie Hopkin, Kathryn R. Malpas et al.
Harnessing New Potential in Generalized Myasthenia Gravis (gMG): When Individuality Meets Optionality
Sonia Caraballo, Neelam Goyal, Nicholas Silvestri et al.
Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomized, parallel-group study
Joseph F Merola, Iain B McInnes, Philip J Mease et al.
HEADFIRST: Preliminary Results From Home Sleep EEG Testing in Patients With LGS
Jay Pathmanathan, Franz Fürbass, Anna Marszalek et al.
Healthcare Utilization and Persistence in Patients With Dravet Syndrome: A Retrospective Analysis Using US Claims Data
Derek Ems, MPH, Srihari Jaganathan et al.
Impact of Bimekizumab on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from the BE MOBILE 1 and 2 Phase 3 Studies
Maksymowych P. Walter, Ramiro Sofia, Poddubnyy Denis et al.
Impact of fenfluramine on convulsive seizure frequency in dose-capped patients with Dravet syndrome
Rima Nabbout, Kelly G. Knupp, Lieven Lagae et al.
Impact of prolonged seizures on patients’ and caregivers’ quality of life
Danya Kaye, Michelle Manzo, Andrea Wilkinson et al.
Impact of Prolonged Seizures on Patients’ and Caregivers’ Quality of Life
Danya Kaye, Michelle Manzo, Andrea Wilkinson et al.
Inhalation as an Efficient Delivery Route of Alprazolam for the Treatment of Acute Seizures: Randomized Study of Staccato®Alprazolam Relative to Oral Alprazolam
Tony Daniels, Ronald Goldwater, Andrea Ford et al.
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Tania Rowley, Adnan R. Khan, Laura McLaughlin et al.
Insights into Lennox-Gastaut Syndrome: A European Real-World Study on Patient Profiles and Unmet Needs
Adam Strzelczyk, Antonio Gil-Nagel, Pasquale Striano et al.
Interactions of Fcy receptors with an IgG4 format, anti-FcRn monoclonal antibody, rozanolixizumab
Qureshi S Omar, Rosemary F Bithell, Cutler M. Rona et al.
Interim results of the US fenfluramine oral solution cardiovascular safety registry study
Almasa Bass, Diego Morita, Julie Shepherd-Smith et al.
Interim Results of the US Fenfluramine Oral Solution Cardiovascular Safety Registry Study
Almasa Bass, Diego Morita, Julie Shepherd-Smith et al.
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Pinter Andreas, Augustin Matthias, Pariser David et al.
Long-Term Efficacy and Tolerability of Brivaracetam in Pediatric Patients With Focal-Onset Seizures and Cognitive or Learning Comorbidities: Post Hoc Analysis of an Open-Label Trial
Lieven Lagae, Dimitrios Bourikas, Najla Dickson et al.
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Deodhar Atul, Navarro-Compán Victoria, Poddubnyy Denis et al.
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
Deodhar Atul, Navarro-Compán Victoria, Poddubnyy Denis et al.
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
James F. Howard Jr., Freimer Miriam, Genge Angela et al.
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
James F. Howard Jr., Freimer Miriam, Genge Angela et al.
Long-Term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT
James F. Howard Jr., Freimer Miriam, Genge Angela et al.
Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: Updated results from phase 2b/3 studies and their open-label extensions
Joseph F. Merola, Mease J. Philip, Poddubnyy Denis et al.
Long-term safety of repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis
Vu Tuan, Grosskreutz Julian, Gayfieva Maryam et al.
Long-term safety outcomes of rozanolixizumab treatment in patients with generalized myasthenia gravis: A pooled analysis
Vissing John, Grosskreutz Julian, Habib A. Ali et al.
Long-Term Sustained Efficacy and Safety of Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Xenofon Baraliakos, Deodhar Atul, Desiree van der Heijde et al.
Long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: 2-year results from two phase 3 studies
Xenofon Baraliakos, Deodhar Atul, Desiree van der Heijde et al.
Long-Term Tolerability and Efficacy of Adjunctive Brivaracetam in Pediatric Patients With Primary Generalized Seizures: Subgroup Analysis of an Open-Label, Follow-Up Trial
Lieven Lagae, Christine de la Loge, Sami Elmoufti et al.
Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with primary generalized seizures: subgroup analysis of an open-label, follow-up trial
Lieven Lagae, Christine de la Loge, Sami Elmoufti et al.
Long-term zilucoplan in generalized myasthenia gravis: 96-week follow-up interim analysis of RAISE-XT
James F. Howard Jr., M. Isabel Leite, Bresch Saskia et al.
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Irene E. van der Horst-Bruinsma, Matthew A. Brown, Floris A. van Gaalen et al.
Maintenance of stringent clinical responses with bimekizumab in patients with axial spondyloarthritis: 2-year outcomes from two phase 3 studies
Gottlieb B. Alice, Proft Fabian, Desiree van der Heijde et al.
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis Over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
Xenofon Baraliakos, Ramiro Sofia, Maksymowych P. Walter et al.
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 years of Bimekizumab Treatment: Results from a Phase 3 Open-label Extension Study
Xenofon Baraliakos, Ramiro Sofia, Maksymowych P. Walter et al.
Minimal symptom expression in generalized myasthenia gravis: A post hoc analysis of MycarinG and open-label studies
Vissing John, Antozzi Carlo, Drużdż Artur et al.
Mitochondrial Myopathies Mimicking Neuromuscular Diseases: A Case-Based Exploration
Tahseen Mozaffar et al.
Modeling Systemic Exposure to Fenfluramine and its Active Metabolite, Norfenfluramine, in Patients With Dravet Syndrome
Aravind Mittur, Christopher Rubino, Stéphane Auvin et al.
Non-steroidal immunosuppressant therapy changes during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Vu Tuan, Freimer Miriam, Genge Angela et al.
Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment
Cutcutache Ioana, Rastrick Joe, Ferecsko Alex et al.
Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
Habib A. Ali, Pascuzzi M. Robert, Vissing John et al.
Onset and Duration of Adverse Events in Patients Treated With Fenfluramine in the Lennox-Gastaut Syndrome Clinical Trials
Joseph Sullivan, Lieven Lagae, Raman Sankar et al.
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization Among Patients With Epilepsy on Brivaracetam Monotherapy: A Cohort Study Using US Claims Data
Beade Numbere, Hervé Besson, Anna Kuba et al.
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Dubreuil Maureen, Magrey Marina, Haeffs Kathrin et al.
Patient experiences of thymidine kinase 2 deficiency (TK2d): preliminary results from an online survey conducted in partnership with the patient community
Balcells Cristy, Karaa Amel, Waller Katie et al.
Patient Preferences for Myasthenia Gravis Treatments: A Discrete-Choice Experiment
Mansfield Carol, Ho Kerrie-Anne, Pierce Anna et al.
Patient-Reported Outcomes in Adults With Focal-Onset Seizures Who Completed 12 Months of Adjunctive Brivaracetam in Earlier Treatment Lines: Post Hoc Analysis of Interim Real-World Data From BRITOBA
Dimitrios Bourikas, Edouard Hirsch, Christine de la Loge et al.
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
M. Elaine Husni, Philip J Mease, Gladman D. Dafna et al.
Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label, Phase 1b CHERISH Study
Megan E. B. Clowse, Dolhain Radboud, Finzel Stephanie et al.
Pharmacokinetics of Fenfluramine and its Active Metabolite Norfenfluramine in Patients with Lennox-Gastaut Syndrome
Aravind Mittur, Christopher Rubino, James Wheless et al.
Point-Counterpoint: An Expert-led Discussion on Generalized Myasthenia Gravis (gMG) Treatment Choice
Christyn Edmundson, Ali Habib et al.
Post-Hoc Analysis of Fenfluramine for Lennox-Gastaut Syndrome by Baseline Frequency Quartiles of Seizures Associated With a Fall
Kelly G. Knupp, Rima Nabbout, Ingrid E. Scheffer et al.
Preliminary baseline results from the CANDID study: An observational study in patients with CDKL5 Deficiency Disorder
Liogier d’Ardhuy X., Aimetti A. , Di Nardo A. et al.
Pulmonary safety of Staccato®alprazolam in healthy participants and participants with mild asthma: phase 1, randomised, double-blind, placebo-controlled trial
S David Miller, Craig F LaForce, Laura Barlow et al.
Purified monoclonal rheumatoid factors bind to Fc containing TNF inhibitors in vitro but not to the Fc-free TNF inhibitor, certolizumab pegol
R Bidgood Susanna, M Kallenberg David, O’Neill Jacqueline et al.
Rapid joint and skin responses were observed in patients with active psoriatic arthritis treated with bimekizumab: A pooled analysis from two phase 3 studies
Behrens Frank, Coates C. Laura, Nash Peter et al.
Rapid, Sustained Improvements in Routine Assessment of Patient Index Data 3 in Bimekizumab-Treated Patients With Psoriatic Arthritis: Post-Hoc Analysis of Two Phase 3 Studies
Kavanaugh Arthur, Ogdie Alexis, Rahman Proton et al.
Rare Disease Connect in Neurology (RDCN): An international MG community and forum providing needs-driven medical education
James F. Howard, Jr., M.D. et al.
Real world use of fenfluramine for Dravet syndrome: a retrospective cohort study using a national pharmacy database
Wesley T. Kerr, Samden D Lhatoo, Elaine C. Wirrell et al.
Real-World Use and Associated Healthcare Resource Utilization Among Patients With Epilepsy Receiving Rescue Midazolam Nasal Spray
Jeannette Novatski, Hillary Doyle, Amelia Boehme et al.
Real-World Use of Fenfluramine for Dravet Syndrome: A Retrospective Cohort Study Using a National Pharmacy Database
Wesley T Kerr, Samden D Lhatoo, Elaine C Wirrell et al.
Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis
Habib A. Ali, Sacconi Sabrina, Pascuzzi M. Robert et al.
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Magrey Marina, Poddubnyy Denis, Lebwohl Mark et al.
Reporting mental health and associated disorders from trials of bimekizumab in patients with active axial spondyloarthritis and psoriatic arthritis
Magrey Marina, Poddubnyy Denis, Lebwohl Mark et al.
Response rates with zilucoplan among generalized myasthenia gravis patients in an interim analysis of RAISE-XT, a Phase 3 open-label extension study
Vu Tuan, M. Isabel Leite, Mantegazza Renato et al.
Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT
James F. Howard Jr., Freimer Miriam, Genge Angela et al.
Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis
Pascuzzi M. Robert, Grosskreutz Julian, Habib A. Ali et al.
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
Vu Tuan, Habib A. Ali, Pascuzzi M. Robert et al.
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
Vu Tuan, Habib A. Ali, Pascuzzi M. Robert et al.
Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: Post hoc analysis
Habib A. Ali, Vu Tuan, Utsugisawa Kimiaki et al.
Safety and Effectiveness of Adjunctive Fenfluramine in an Open-Label Extension Study of Children (Under 6 Years Old) With Dravet Syndrome
Ingrid E. Scheffer, Rima Nabbout, Lieven Lagae et al.
Safety and effectiveness of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: results from the final analysis of an open-label extension study
Kelly G. Knupp, An-Sofie Schoonjans, Joseph Sullivan et al.
Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)
Bril Vera, Grosskreutz Julian, Habib A. Ali et al.
Safety, Efficacy, and Patient Preference for Subcutaneous Zilucoplan in Myasthenia Gravis After Switching from Intravenous Complement 5 Component 5 Inhibitors: An Interim Analysis of a Phase 3b Study
Freimer Miriam, Govindarajan Raghav, Khatri Bhupendra et al.
Safety, tolerability, pharmacokinetics, and efficacy of fenfluramine in combination with cannabidiol: results from an exploratory phase 1 study
Rebecca Zhang Roper, Aravind Mittur, Brooks Boyd et al.
Self-administration of rozanolixizumab in patients with generalized myasthenia gravis: The MG0020 study
Bril Vera, Antozzi Carlo, Berkowicz Tomasz et al.
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
Rachana K. Gandhi Mehta, Bril Vera, Antozzi Carlo et al.
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
Rachana K. Gandhi Mehta, Bril Vera, Antozzi Carlo et al.
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Gottlieb B. Alice, Maul Julia-Tatjana, Spelman Lynda et al.
Sleep apnea is associated with high mortality risk in children with severe epilepsies: an observational analysis from large scale US claims data
Stefanie Dedeurwaerdere, Daniel Lloyd, Alexis Davis et al.
Sleep Apnea is Associated With High Mortality Risk in Children With Severe Epilepsies: An Observational Analysis From Large Scale US Claims Data
Stefanie Dedeurwaerdere, Daniel Lloyd, Alexis Davis et al.
Social determinants of health are associated with delayed diagnosis in myasthenia gravis
Thompson Judith, Zhang Bo, Liberman N. Joshua et al.
Solutions to address the unmet needs of the gMG patient journey in the US: A multistakeholder Delphi consensus study
Thompson Judith, Victoria Mroczek, Arthi Padmanabhan et al.
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Puig Luis, Gisondi Paolo, Pinter Andreas et al.
Subcutaneous Infusions in Generalized Myasthenia Gravis: Understanding the Administration of Rozanolixizumab-noli
Chandra Shaw et al.
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Marzo-Ortega Helena, Philip J Mease, Dougados Maxime et al.
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Marzo-Ortega Helena, Mease J. Philip, Dougados Maxime et al.
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Navarro-Compán Victoria, Dubreuil Maureen, Gaffney Karl et al.
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study
Freimer Miriam, Desai Urvi, Govindarajan Raghav et al.
Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study
James F. Howard Jr., Desai Urvi, Govindarajan Raghav et al.
Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study
Freimer Miriam, Desai Urvi, Govindarajan Raghav et al.
The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)
Bril Vera, Drużdż Artur, Grosskreutz Julian et al.
Time Course of Treatment-Emergent Adverse Events in Adult Asian Patients With Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: A Post Hoc Analysis of a Phase III, Randomized Trial
Naotaka Usui, Dong Zhou, Bin Qin et al.
Time to Diagnosis and Associated Comorbidity Burden in Axial Spondyloarthritis in General Practice in France: Results from the THIN® Database
Prati C., Constantin A., Dernis E. et al.
Tolerability and Efficacy of Adjunctive Brivaracetam in Japanese and Chinese Patients With Focal-Onset Seizures: Interim and Post Hoc Analysis of a Phase 3, Open-Label Extension Trial
Ayataka Fujimoto, Bing Qin, Dong Zhou et al.
Treatment satisfaction, work productivity, and quality of life under adjunctive brivaracetam in earlier treatment lines in adults with focal-onset seizures: 12-month real-world data from BRITOBA
Yaroslav Winter, Giovanni Boero, Giuseppe Didato et al.
Understanding the incidence, prevalence, characteristics, and healthcare resource utilization for patients with Dravet and Lennox-Gastaut syndromes
Rejena Ameen, Joseph Sullivan, Elaine C. Wirrell et al.
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Ogdie Alexis, Song Chao, Middaugh Nicole et al.
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Philip J Mease, Poddubnyy Denis, Bajracharya Rajan et al.
Utilizing Patient-Reported Data to Improve Understanding of Flare Predictors in Patients with Moderate to Severe Hidradenitis Suppurativa
Maria A. Aleshin, Andres-Terre Helena, Tran Tanja et al.
Watch Video: Clinical Relevance of High Rheumatoid Factor in Patients with Rheumatoid Arthritis
Smolen J et al.
What Are the Experiences of Women of Childbearing Age With Epilepsy Throughout Their Motherhood Journey? Results From a Social Media Listening Study
Gus A Baker, Dimitrios Bourikas, Agnes Koncz et al.